Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
Subscribe To Our Newsletter & Stay Updated
